Bibliografía
 

2. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979; 43:1242-1244.

3. Maron BJ. Hypertrophic cardiomyopathy. Curr Probl Cardiol 1993; 18:637-704.

4. Maron BJ, Cecchi F, McKenna WJ. Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J 1994; 72 (supl):13-18.

5. Wigle DE, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, y cols. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985; 28: 1-83.

6. Stewart S, Schreiner B. Coexisting idiopathic hypertrophic subaortic stenosis and coronary artery disease. Clinical implication and operative management. J Thorac Cardiovasc Surg 1981; 82: 278.

7. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmias in hypertrophic cardiomyopaty. Y. Influence on prognosis. Br Heart J 1981; 46: 168-172. 

8. Savage DD, Seides SF, Maron BJ, Myers DM, Epstein SE. Prevalence of arrhythmias during 24-hours electrocardiographic monitoring and exercise testing in patients with obstructive and non obstructive hypertrophic cardiomyopathy. Circulation 1979; 59: 866-875.

9. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, y cols.  Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and non sustained ventricular tachycardia. Circulation 1994; 90: 2743-2747.

10. Fananapazir Y, Chang AC, Epstein ND, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of therapeutic strategy based on clinical, Holter, hemodinamic and electrophysiological findings. Circulation 1992; 86: 730-740.

11. Panza JA, Petrone RK, Fananazapir L, Maron BJ. Utility of continuous Wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19:91-99.

12. Stewart WJ, Schiavone WA, Salcedo EE, Lever HM, Cosgrove DSM, Gill CC. Intraoperative Doppler echocardiography in hypertrophic cardiomyopathy: correlations with the obstructive gradient. J Am Coll Cardiol 1987; 10: 327-335.

13. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation 1989; 80: 1489-1492.

14. McKenna WJ, Deanfield JE. Hypertrophic cardiomyophathy: an important cause of sudden death. Arch Dis Child 1984; 59:971-975.

15. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993; 72: 970-972.

16. Bourmayan C, Razavi A, Fournier C, Dussaule JC, Baragan J, Gerbaux A, Gay J. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. Am Heart J 1985; 109: 1311-1316.

17. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short and long term effects. Circulation 1985; 72: 853-864.

18. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981; 64: 437-441.

19. Millaire A, Goullard L, Decoulx E, De Groote P, Houdas Y, Ducloux G. Efficiency of disopyramide in hypertrophic cardiomyopathy during stress states. Am J Cardiol 1992; 69: 423-442. 

20. The Cardiac Arrhytmia Supression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhytmia supression after myocardial infarction. N Engl J Med 1989; 321: 406-412.

21. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-417.

22. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhytmias and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11: 147-153.

23. McKenna WJ, Adams KM, Poloniecki JD, Dickie S, Oakley CM, Krikler DM, Goodwin JF. Long term survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Circulation 1989; 80:6.

24.  Shah PM, Adelman AG, Wigle DE, y cols. The natural (and unnatural) history of hypertrophic cardiomyopathy. Cir Res 1974; 34: 179-184.

25. McIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation 1988; 78: 487-495.

26. McIntosh CL, Maron BJ, Cannon RO, y cols. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation 1992; 86: II 60-7.

27. Grigg LE, Wigle DE, Williams WG, y cols. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision-making. J Am Coll Cardiol 1992; 20: 42-53.

28. Marwick TH, Stewart WJ, Lever HM, y cols. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 20: 1066-1072.

29. Seiler C, Hess OM, Schoenbeck M, Turina J, Jenni R, Turina M, y cols. Long-term follow up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol 1991; 17: 634-642.

30. Penas M, McKenna WJ. El tratamiento quirúrgico precoz de la miocardiopatia hipertrófica obstructiva sintomática. Argumentos a favor. Rev Esp Cardiol 1995; 48:223-228.

31. McDonald KM, Maurer B. Permanent pacing as treatment for hypertrophic cardiomyopathy. Am J Cardiol 1991; 68: 108-110.

32. Fananapazir L, Cannon RO, Tripodi D, y cols. Impact of dual chamber permanent pacing in patients with hypertrophic obstructive cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation 1992; 85: 2149-2161.

33. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992; 339:1318-1323.

34. Blanch P, Soto A, Tornos P, Bosch R, Evangelista A, Soler J. Marcapasos VVI en el tratamiento de la miocardiopatía hipertrófica obstructiva en fibrilación auricular. Rev Esp Cardiol 1993; 46: 455-477.

35. Fananazapir L, Epstein ND, Curiel RV, y cols. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994; 90:2731-42.

36. Slade AKB, Sadoul N, Shapiro L, y cols. DDD pacing in hypertrophic cardiomyopathy: a multicenter clinical experience. Heart 1996; 75: 44-9.

37. Spirito P, McKenna WJ, Schultheiss HP. DDD pacing in obstructive HCM (letter). Circulation 1995; 92: 1670-1.

38. Nishimura RA, Danielson GK. Dual chamber pacing for hypertrophic obstructive cardiomyopathy: has its time come? (Editorial). Br Heart J 1993; 70:301-3.

39. Tripodi D, McAreavey D, Epstein ND, Fenanapazir L. Impact of the implantable defibrillator in hypertrophic cardiomyopathy patients with at high risk for sudden death (resumen). J Am Coll Cardiol 1993; 21:352.

40. O´Donoghue S, Platia E, Mispireta L, y cols. Safety of desfibrillator implantation in patients with hypertrophic cardiomyopathy (resumen). J Am Coll Cardiol 1994; 11.

41. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 1980 ; 44 : 672-675.

42. Komadja M, Jais P, Reeves F. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 1990 ; 11 : 824-831.

43. Archard LC, Bowles EN, Olsen EGJ, Richardson PJ. Detection of persistent Coxsackie B virus RNA in dilated cardiomyopathy and myocarditis. Eur Heart J 1987 ; 8 (Suppl J) : 437-440.

44. Coughlin SS, Szklo M, Baughman K, Pearson TA. The epidemiology of idiopathic dilated cardiomyopathy in a biracial community. Am J Epidemiol 1990 ; 131 : 48-56.

45. Janicki JS, Myocardial collagen remodelling and left ventricular diastolic function. Braz J Med Biol Res 1991 ; 25 : 975-982

46. Hein S, Scholz D, Fujitani H, et al. Altered expression of titin and  contractile proteins in failing human myocardium. J Mol Cell Cardiol 1994 ;26 :1291-306.

47. Braunwald E, Sonnenblick EH, Ross J Jr. Mechanisms of cardiac contraction and relaxation. En : Braunwald E, ed. Heart Disease. Philadelphia, Saunders 1988 ;383-425.

48. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output heart failure, nephrotic syndrome, cirrhosis and pregnancy. N Englo J Med 1988 ; 319 :1065-1127.

49. Ferrari R, Anand I. Cambios neurohormonales en la insuficiencia cardíaca no tratada. En : Cortina A, ed .  Insuficiencia cardíaca. Oviedo, JR Prous De 1992, pp. 57-67.

50. Francis GS, Cohn JN, Johnson G, Rector TS, Goldmans, Siman A. Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure : Relations to Survival and the Effects of Therapy in V-HeFT II. Circulation 1993 ; 87 :VI-40-VI-48.

51. Pouleur H. Role of Neurohormones in Ventricular Adaptation and Failure. Am J Cardiol 1994 ;73 :36C-39C.

52. Benedict CR, Weine DH, Johnstone DE, Bourassa MC et al. Comparative Neurohormonal Responses in Patients With Preserved and Impaired Left Ventricular Ejection Fraction : Results of de Studies of Left Ventricular Disfunction (SOLVD) Registry. JACC 1993 ; 22 (Suppl A) : 146A- 153A.

53. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Cir Res 1988 ;62 :191-195.

54. Cody RJ, Atlas SA, Laragh JH et al. Atrial natriuretic factor in normal subjects and heart failure patients : plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 1986 ; 78 : 1362-1374.

55. Levine B, Kulman J, Mayer L, et al. Elevated circulating levels at tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990 ; 323 : 236-41.

56. Miller W, Redfield M, Burnett JC Jr. Integrated cardiac, renal and endocrine actions of endothelin. J Clin Invest 1989 ; 83 :317-320.

57. Aurback GD, Fedak SA, Woodard CJ, Et al. Beta-Adrenergic receptor : stereospecific interaction of iodinated beta-blocking agent with high affinity site. Science 1974 ;186 :1223-4.

58. Fowler MB, Laser JA, Hopkins GO, et al. Assessment of the Beta-Adrenergic receptor pathway in the intact failing human heart : pregressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986 ;74 :1290-1302.

59. Bristow MR, Hershberge RE, Port JD, et al. Beta1 and Beta2 adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989 ; 35 :295-303.

60. Jacobs RC, Gerhengorh K, Chait A. Dysfagia associated with a distented pulmonary vein. Br J Radiol 1972 ; 45 :225-228.

61. Fuster V, Gersh BJ, Giulani ER et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981 ; 47 : 525-531.

62. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN, Incidence of thromboembolic events in congestive heart failure. Circulation 1993 ; 87(Suppl 6) : 94-101.

63. Meinertz T, Hofmann T, Kasper W et al. Significance of ventricular arrhythmias in idiopathic dilate cardiomyopathy. Am J Cardiol 1984 ;53 : 902.

64. Bayés de Luna A. Electrocardiografia en las distintas cardiopatías y en situaciones diversas. En : Bayés de Luna A. Tratado de Electrocardiografía Clínica. Madrid 1987 ; 493-494.

65. Teichholz LE, Klenleu T, Herman MV et al. Problems in echo cardiographic volume determinations : Echocardiographic-angiographic correlations in the present or absence of asynergy. Am J Cardiol 1976 ;37 :7.

66. Nixon JV, Narahara KA, Smitherman TC. Stimation of myocardial involvement in patients with acute myocardial infarction by two-dimensional echocardiography. Circulation 1980 ; 62 :1248.

67. Heger JJ, Weymann AE, Wann LS et al. Cross-sectional echocardiography in acute myocardial infarction ; detection and localization of regional left ventricular asynergy. Circulation 1979 ;60 :531.

68. Estorch N, Carrió I, Artigas A et al. Volúmenes biventriculares absolutos y gasto cardíaco por ventriculografía isotópica. Rev Esp Cardiol 1988 ; 41 :97.

69. Popma JJ, Cigarroa RG, Buja LM, Hillis LD. Diagnostic and prognostic utility of right-sided catheterization and endomyhocardial bioopsy in idiopathic dilated cardiomyopathy. Am J Cardiol 1989 ; 63 : 955-958.

70. Valles F, Anguita M, Arizón JM, Latre JM, Giménez D, Torres F et al. Factors predicting long-term outcome in patients with acute myocarditis. J Am Coll Cardiol 1994 ; 23 (Supl) :364A.

71. Urbano-Márquez A, Estruch R, Navarro-López F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989 ; 320 :409-15.

72. Taraschi TF, Rubin E. Effects of ethanol on the chemical and structural properties of biological membranes. Lab Invest 1985 ; 52 : 120-31.

73. Alling C, Gustavsson L, Mansson JE, Benthin G, Anggard E. Phosphatidyl-ethanol formation in rat organs after ethanol treatment. Biochim Biophys Acta 1984 ;793 :119-22.

74. Laposata EA, Lange LG. Presence of nonoxidative ethanol metabolims in human organs commonly damaged by ethanol abuse. Science 1986 ; 231 : 497-499.

75. Israel Y. Hurwitz E. Niemela O, Arnon R. Monoclonal and polyclonal antibodies against acetaldehide-containing epitopes in acetaldehyde-protein adducts. Proc Natl Acad Sci USA 1986 ; 83 :7923-7927.

76. Garrett JS, Wikman-Coffelt J, Sievers R, Finkbeiner WE, Parmley WW. Verapamil prevents the development of alcoholic dysfunction in hamster myocardium. J Am Coll Cardiol 1987 ; 9 : 1326-1331.

77. Kaul S, Fishbein MC, Siegel RJ. Cardiac manifestations of acquired immune deficiency syndrome ; 1991 update. Am Heart J 1991 ; 122 :535-544. 

78. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992 ; 327 : 685-691.

79. The captopril-digoxin multicenter research group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988 ; 259 : 539-544.

80. Hochleitner M, Hortnagl H, Choi-Keung NG, Hortnagl H, Gschnitzer F, Zechmann W. Usefulness of physiologic dual-chamber pacing in drug-resistant idiopathic dilated cardiomyopathy. Am J Cardiol 1990 ; 66 : 198-202.

81. Report of WHO/ISFC Task Force. Definition and classification of cardiomyopathies. Br Heart J 1980 ; 44 : 672-673.

82. Fitzpatrick AP, Shapiro LM, Rickards AF, Poole-Wilson PA. Familial restrictive  cardiomyopathy with atrioventricular block and skeletal myopathy. Br Heart J 1990 ;  63 : 114.

83. Johnson RA, Palacios IF. Non-dilated cardiomyopathies. Adv Intern Med 1984 ; 30 :  243-74.

84. Hosenpud JD. Restrictive cardiomyopathy. In Zipes DP and Rowlands DJ (eds.). Progress in Cardiology. Philadelphia, Lea and Febiger, 1989, p.91. 

85. Lewis AB. Clinical profile and outcome of restrictive cardiomyopathy in children. Am Heart J 1992 ; 123 : 1589-1593.

86. Child JS, Perloff JD. The restrictive cardiomyopathies. Cardiol Clin 1988 ; 6 :289.

87. Bayés de Luna A. La Electrocardiología en las distintas cardiopatías y en situaciones diversas. En : Bayés de Luna A. Tratado de Electrocardiografía Clínica. Madrid 1987 ; 494.

88. Shabetai R, Fowler NO, Gunheroth WG. The hemodynamics of cardiac tamponade and constrictive pericarditis. Am J Cardio 1970 ; 26 : 480-489. 

89. Hanser AT, Eskildsen P, Gotzsche H. Pressure curves from the right auricle and right ventricle in chronic constrictive pericarditis. Circulation 1951 : 3 : 881-885. 

90. Katritsis D, Wilmshurst PT, Wendon JA, Davies MJ, Webb-Peoploe MM. Primary  restrictive cardiomyopathy : clinical and pathologic chareacteristics. J Am Coll Cardiol 1991 ; 18 : 1230-1235.

91. Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function : new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988 ; 12 : 426-440

92. Janos GG, Arjunan K, Meyer RA, Engel P, Kaplan S. Differentiation of constrictive pericarditis from restrictive cardiomyopathy using  digitized echocardiography. J Am Coll Cardiol 1983 ; 1 : 541-549.

93. Falk RH. Cardiac Amyloidosis. In Zipes DP and Rowlands DJ (eds.) : Progress in Cardiology. Philadelphia, Lea and Febiger, 1989 ; p.143.

94. Shaper AG. What’s new in endomyocardical fibrosis ? Lancet 1993 ; 342 : 255-256.

95. Gupta PN, Valiathan MS. Balakrishnan KG et al. Clinical course of endomyocardial fibrosis. Br Heart J 1989 ; 62 : 450.

96. Olsen EGJ and Spry CJF. Relation between eosinophilia and endomyocardial disease. Prog Cardiovasc Dis 1985 ; 27 : 241.

97. Lundin L. Norheim I, Landelius J et al. Carcinoid Heart Disease : Relacionship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988 ; 77 : 264.

98. Wyne J, Braunwald E. The cardiomyopathies and myocarditides: toxic, chemical, and physical damage to the heart. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 4th de. Vol 2. Philadelphia. W.B. Saunders. 1992: 1394-1450.

99. Peters NS, Poole-Wilson PA. Myocarditis: continuing clinical and pathological confusion. Am Heart J 1991; 121:942-947

100.  Karjalainen J,  Heikkila J, Nieminen M et al. Etiology of mild acute infectious myocarditis. Relation to clinical features. Acta Med Scand 1983;213: 65-73. 

101.  Homans DC. Peripartum cardiomyophaty. N Engl J Med 1985; 312.1432-1436.

102.  Davidoff R, Palacios Y, Southern J, Fallon JT, Newell J, Dec GW. Giant cell versus lymphocytic myocarditis: A comparison of their clinical features and long-term outcomes. Circulation 1991; 83:953-961.

103.  Gravanis MG, Sternby NH. Incidence of myocarditis. Arch Pathol Lab Med 1991; 15:390-392.

104.  Barry WH . Mechanisms of inmune-mediated myocyte injury. Circulation 1994; 5:2421-32.

105.  Lange LG, Schreiner GF. Inmune mechanisms of cardiac disease. N Engl J Med 1994; 16:1129-1135.

106.  Yeh ET. Autoinmunity and the pathogenesis of myocarditis. Circulation 1994; 3:1318-1319.

107.  Narula J, Khaw BA, Dec GW, Palacios IF, Southern JF, Fallon JT, Strauss HW, Haber E, Yasuda T. Brief report: recognition of acute myocarditis masquerading as acute myocardial infarction. N Engl J Med 1993; 328:100-104.

108.  McCaffrey FM, Braconier DS, Strong WB. Sudden cardiac death in young athletes. Am J Dis Child 1991; 145:177-183.

109.  Morgera T, Di Lenarda A, Dreas L, Pinamonti B, Humar F, Bussani R, Silvestri F, Chersevani D, Camerini F. Electrocardiography of myocarditis revisited: Clinical and prognostic significance of electrocardiographic changes. Am Heart J 1992; 124:455-467.

110.  William Dec G, Palacios Y, Yasuda T, Fallon JT, An Khaw B, William Strauss H, Haber E. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990; 16:97-104.

111.  Mason JW. Techniques for right and left ventricular endomyocardial biopsy. Am J Cardiol 1978; 41:887-892.

112.  Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ, Olsen EGJ, Schoen FJ. Myocarditis: a histopatological definition and classification. Am J Cardiovasc Pathol 1987; 1:3-14.

113.  Richardson PJ, Olsen EGJ, Jewitt DE, Oram S. Percutaneous technique of left ventricular biopsy, and comparison between right and left ventricular myocardial samples. Br Heart J 1975; 37:556.

114.  Dec GW, Fallon JT, Southern JF, Palacios Y. “Borderline” myocarditis: An indication for repeat endomyocardial biopsy. J Am Coll Cardiol 1990; 15:283-289.

115.  Davies MJ, Ward DE. How can myocarditis be diagnosed and should it be treated? Br Heart J (Ed) 1992; 68:346-347.

116.  Millaire A, De Groote P, Decoulx E, Leroy O, Ducloux G. Outcome after thrombolytic therapy of nine cases of myopericarditis misdiagnosed as myocardial infarction. Eur Heart J 1995; 16: 333-338.

117.  Ilback NG, Fohlman J, Friman G. Exercise in coxsackie B3 myocarditis: Effects on heart lymphocyte subpopulations and the inflammatory reaction. Am Heart J 1989; 117:1298-1301.

118.  Rezkalla S, Kloner RA, Khatib G Khatib R. Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation 1990; 81:1039-1042.

119.  Rockman HA, Adamson RM, Dembitsky WP, Bonar JW, Jaski BE. Acute fulminant myocarditis: long term follow-up after circulatory support with left ventricular assist device. Am Heart J 1991; 121:922-926.

120.  Mortensen SA, Baandrup U, Buch J, Bendtzen K, Hvid-Jacobsen K. Inmunosuppressive therapy of biopsy proven myocarditis: experiences with corticosteroids and cyclosporin. Int J Immunother 1985; 1:35-45.

121. Jones SSR, Herskowitz A, Hutchins GM, Baughman KL. Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function. Am J Cardiol 1991; 68:370-376.

122.  Mason JW, O´Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE and the Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333:269-275.

123.  Maisch B, Hufnagel G, Schonian U, Hengstenberg C et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). European Heart Journal 1995;16S: 173-175.

124.  O´Connell JB, Dec GW, Billingham ME, Goldenberg IF, Starling RC, Mudge GH, Augustine SM, Costanzo-Nordin MR et al. Results of cardiac transplantation in active myocarditis (Abstract). J Heart Transplant 1989; 8:99.

125.  Maisch B, Herzum M, Hufnagel, Bethge C, Schonian U. Inmunosuppresive treatment for myocarditis and dilated cardiomyopathy. European Heart Journal 1995; 16S: 153-161.